Old Web
English
Sign In
Acemap
>
authorDetail
>
F Braegger
F Braegger
Takeda Pharmaceutical Company
Medicine
Vedolizumab
Internal medicine
Crohn's disease
Physical therapy
5
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
P285 A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn’s disease
2021
Journal of Crohn's and Colitis
Roni Weisshof
Stephan R. Vavricka
L. Pouillon
F Braegger
M. Roset
N. Bent-Ennakhil
Marc Ferrante
Show All
Source
Cite
Save
Citations (0)
P406 A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries
2021
Journal of Crohn's and Colitis
Uri Kopylov
Johan Burisch
Shomron Ben-Horin
F Braegger
Alonso Fernández-Nistal
N. Lara
Stephan R. Vavricka
Show All
Source
Cite
Save
Citations (0)
P523 Survey to identify patient characteristics, treatment preferences and impact of inflammatory bowel disease (IBD) on quality of life across 7 countries in Europe
2021
Journal of Crohn's and Colitis
G. Fiorino
N. Bent-Ennakhil
P. Varriale
F Braegger
E Hoefkens
Show All
Source
Cite
Save
Citations (0)
P583 Efficacy of vedolizumab (VDZ) by disease extension in ulcerative colitis
2018
Journal of Crohns & Colitis
P. Michetti
F Braegger
C Kempf
Matthieu Allez
Show All
Source
Cite
Save
Citations (0)
P727 Efficacy of vedolizumab (VDZ) by disease localisation in Crohn’s disease
2018
Journal of Crohns & Colitis
Matthieu Allez
F Braegger
C Kempf
P. Michetti
Show All
Source
Cite
Save
Citations (0)
1